In Silico Development of a Multi-epitope Vaccine Targeting TFDP3: A Novel Approach for Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Rising cancer incidence necessitates novel anti-tumor therapies.
• Targeted therapies using cancer testicular antigens (CTAs) show promise due to tumor-specific expression.
• TFDP3 is a CTA found in various cancers, including triple-negative breast cancer and hepatocellular carcinoma.

Purpose of the Study:

• To design a multi-epitope vaccine targeting TFDP3 using immunoinformatics.
• To identify and select potent T-cell and B-cell epitopes for vaccine development.
• To evaluate the vaccine's in-silico properties, including stability, immunogenicity, and population coverage.

Main Methods:

• Immunoinformatics tools were employed to predict antigenic epitopes from TFDP3.
• Epitopes were selected based on antigenicity, allergenicity, toxicity, and IFN-γ induction.
• In-silico analysis assessed vaccine physicochemical properties, homology, and interactions with Toll-like receptors.

Main Results:

• A multi-epitope vaccine construct targeting TFDP3 was computationally designed.
• Selected epitopes demonstrated favorable antigenicity and low predicted toxicity.
• The vaccine construct exhibited high world population coverage (93.55%) for MHC class I and II alleles.
• In-silico analysis indicated favorable stability and potential for inducing a robust immune response.

Conclusions:

• The in-silico designed TFDP3-based vaccine is a promising candidate for cancer immunotherapy.
• Further in vitro and in vivo studies are required to validate its efficacy and safety.
• This vaccine strategy holds potential for treating TFDP3-expressing cancers.